Grifols reported EUR333.1M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 260K Sep/2025
Arca Biopharma USD 5.16M 346K Mar/2025
aTyr Pharma USD 4.8M 130K Sep/2025
Bio Path USD 1.26M 456K Mar/2025
Brainstorm Cell Therapeutics USD 1.78M 319K Mar/2025
Capricor Therapeutics USD 5.88M 1.6M Mar/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Immunic USD -0.24 0.03 Sep/2024
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
TherapeuticsMD USD 1.23M 90K Jun/2024